MedTrace Logo

Ankaferd Blood Stopper for Hemostasis After Transradial Coronary Angiography

NCT02982733 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2016-12-05

No results posted yet for this study

Summary

In 2008 Goker et al, introduced Ankaferd Blood Stopper (ABS) as a new hemostatic drug. Recently, ABS has been shown to produce local hemostasis by implementing topically after major arterial vessel injury. Reducing the compression time during patent hemostasis by facilitating hemostasis may decrease RAO. To test this hypothesis the investigators planned a three arm randomized study to evaluate the safety and efficacy of Ankaferd blood stopper in adjunct to short-time compression, compared to either short-time compression with conventional sterile gauzes or with a TR band after transradial diagnostic procedures.

Conditions

  • Radial Artery Injury
  • Hematoma
  • Bleed

Interventions

OTHER

ABS

Ankaferd Blood Stopper

DEVICE

TR Band

Transradial band

OTHER

CS

Sterile Gauze

Sponsors & Collaborators

  • Acibadem University

    lead OTHER

Principal Investigators

  • Sevket Gorgulu, Prof · Acibadem University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2017-11-30
Completion
2017-12-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02982733 on ClinicalTrials.gov